<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02238522</url>
  </required_header>
  <id_info>
    <org_study_id>ZEN-ONC3365-101</org_study_id>
    <nct_id>NCT02238522</nct_id>
  </id_info>
  <brief_title>Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML</brief_title>
  <official_title>Phase 1 Open-label Dose Escalation and Expansion Study of ZEN003365 in Subjects With Relapsed or Refractory Lymphoproliferative Malignancies or Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zenith Epigenetics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zenith Epigenetics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine safety, tolerability, dose limiting toxicities
      (DLT) and maximum tolerated dose (MTD) of ZEN003365 in patients with relapsed/refractory
      lymphoproliferative malignancies (LPM) or relapsed/refractory acute myeloid leukemia (AML).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose escalation stage - The safety of orally administered ZEN003365, assessed by frequency of adverse events, including worsening of medical conditions/diseases</measure>
    <time_frame>From Day 1 Cycle 1 through the last day of treatment with ZEN003365 (12 weeks, average)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose escalation stage - To characterize the DLTs of orally administered ZEN003365, using NCI CTCAE v4.03</measure>
    <time_frame>The first 25 days of at least 12 doses of ZEN003365</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose expansion stage - Preliminary evidence of the antitumor activity of orally administered ZEN003365 in selected patients, assessed by objective response, duration of objective response and progression-free survival</measure>
    <time_frame>From Day 1 Cycle 1 through the last day of treatment with ZEN003365 (12 weeks, average)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose expansion stage - The safety of orally administered ZEN003365, at the dose chosen based upon the dose escalation stage, assessed by frequency of adverse events, including worsening of medical conditions/diseases</measure>
    <time_frame>From Day 1 Cycle 1 through the last day of treatment with ZEN003365 (12 weeks, average)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose escalation stage - To characterize the pharmacokinetics (PK) of orally administered ZEN003365 in patients, using the following parameters: AUC, Tmax, Cmax, Cmin, pre-dose concentration, and accumulation ratio</measure>
    <time_frame>From Day 1 Cycle 1 through the last day of treatment with ZEN003365 (12 weeks, average)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose expansion stage - To characterize the PK of orally administered ZEN003365, at the dose chosen based upon the dose escalation stage, using the following parameters: AUC, Tmax, Cmax, Cmin, pre-dose concentration, and accumulation ratio</measure>
    <time_frame>From Screening Visit through 40 days after the last day of treatment with ZEN003365 (19 weeks, average)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Lymphoproliferative Malignancies</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Stage - ZEN003365</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZEN003365 will be administered orally as a single agent, enrolling LPM patients and AML patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Stage - ZEN003365</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZEN003365 will be administered orally as a single agent, enrolling LPM patients and AML patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZEN003365</intervention_name>
    <arm_group_label>Dose Escalation Stage - ZEN003365</arm_group_label>
    <arm_group_label>Dose Expansion Stage - ZEN003365</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Dose Escalation and Expansion Stages:

          -  ECOG performance status ≤ 1 for LPM patients, ≤ 2 for AML patients

          -  Age 18 years or older

          -  Adverse events (AEs), except for alopecia, from any previous treatments must have
             recovered to eligibility levels from prior toxicity

          -  Adequate renal, hepatic and coagulation function, as specified per protocol

          -  Written informed consent granted prior to any study-specific screening procedures

        LPM Patients:

          -  Histologically confirmed lymphoproliferative malignancy

          -  Have received prior protocol-specified disease-dependent prior treatments

          -  Have measurable disease

          -  Platelets ≥ 75,000/µL (≥50,000/µL if bone marrow involvement), absolute neutrophil
             count (ANC) ≥ 1,000/ µL, and hemoglobin (Hgb) ≥ 8 g/dL

          -  Patients must have been off previous anticancer therapy for at least 3 weeks or 5
             half-lives, whichever is longer, and the subject must have recovered to eligibility
             levels from prior toxicity

        AML:

          -  Refractory or relapsed AML patients, without curative intent, e.g., not a stem cell
             transplant candidate

          -  Any prior chemotherapy must have been completed ≥ 2 weeks, any therapy with biologics
             must have been completed ≥ 4 weeks prior to day 1 of study treatment, and the
             participant must have recovered to eligibility levels from prior toxicity

          -  Blast count ≤ 10,000/µL prior to initiation of therapy

        Exclusion Criteria

        Dose Escalation and Expansion Stages:

          -  Prior exposure to a BET inhibitor

          -  Prior allogeneic hematopoietic cell transplant

          -  Chronic graft versus host disease

          -  Known, active fungal, bacterial, and/or viral infection

          -  Uncontrolled autoimmune hemolytic anemia or thrombocytopenia

          -  Current subdural hematoma

          -  CNS or leptomeningeal metastases

          -  Requirement for medications or agents known to be sensitive CYP3A4 substrate drugs,
             CYP3A4 substrate drugs with a narrow therapeutic range or to be strong
             inhibitors/inducers of CYP3A4

          -  Requirement for immunosuppressive agents

          -  Evidence of significant cardiovascular disease or significant screening ECG
             abnormalities

          -  Any medical conditions that, in the Investigator's opinion, would impose excessive
             risk to the patient.

        AML patients:

          -  Acute promyelocytic leukemia (APL)

          -  Chronic myeloid leukemia (CML) in blast crisis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute and Research Center</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2014</study_first_submitted>
  <study_first_submitted_qc>September 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2014</study_first_posted>
  <last_update_submitted>November 12, 2014</last_update_submitted>
  <last_update_submitted_qc>November 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic lymphocytic leukemia</keyword>
  <keyword>B-prolymphocytic leukemia</keyword>
  <keyword>Non-Hodgkin's lymphoma</keyword>
  <keyword>follicular lymphoma</keyword>
  <keyword>mantle cell lymphoma</keyword>
  <keyword>marginal zone lymphoma</keyword>
  <keyword>small lymphocytic lymphoma</keyword>
  <keyword>diffuse large B-cell lymphoma</keyword>
  <keyword>unclassifiable lymphoma</keyword>
  <keyword>T-cell lymphoma</keyword>
  <keyword>Richter's syndrome</keyword>
  <keyword>Waldenström's macroglobulinemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

